Director Dealings

RNS Number : 2674L

Oxford Biomedica PLC

17 July 2017

 

Director Dealings / Market Share Purchase

Oxford, UK - 17 July 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 17 July 2017 Peter Nolan, Chief Business Officer, acquired ordinary shares of 1p each ("Ordinary Shares") in the Company as follows:

		Interest after purchase
Price per share (p)	Number of Ordinary Shares (sold)/acquired	Number of Ordinary Shares	% of total issued share capital
8.01p	249,687	1,918,321	0.06%

The issued share capital of the Group is 3,092,108,668 1p ordinary shares.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

DSHZMGMNMNNGNZM